Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Smoking status: not checked. AREDS2 Formula: what these mean for you changes depending on whether you smoke or used to, and you have not told us. That check was skipped.
Head-to-head evidence comparison — which supplement is right for you?
AREDS2 Formula vs Boswellia: Boswellia has the stronger overall evidence (7.5 vs 7/10); the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Boswellia wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Probably helps
2 of 3 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both AREDS2 Formula and Boswellia have evidence — compare verdict strength side-by-side.
One AREDS2 daily regimen, usually split into two servings: vitamin C 500 mg, vitamin E 400 IU, lutein 10 mg, zeaxanthin 2 mg, zinc 80 mg (as zinc oxide) and copper 2 mg (as cupric oxide)
With meals
A product matching the AREDS2 composition exactly: vitamin C 500 mg, vitamin E 400 IU, lutein 10 mg, zeaxanthin 2 mg, zinc 80 mg, copper 2 mg
300-500mg standardized extract (30-40% AKBA), 2-3x daily (a typical label dose, not the dose used in the cited trials, the one that states its dose gave 100 mg a day of Aflapin, standardized to 20% AKBA)
With meals containing fat
Standardized extract (30-40% AKBA or 65% boswellic acids)
and 3 more not shown
Years — average follow-up was 6.3 years
Years
Long-term
Years
4-8 weeks
4-8 weeks
2-4 weeks
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.
JAMA (2013) · Rct · n=4203
Primary analysis was NULL: lutein/zeaxanthin HR 0.90 (98.7% CI 0.76-1.07, P=.12); DHA+EPA HR 0.97 (0.82-1.16, P=.70); both together HR 0.89 (0.75-1.06, P=.10)
A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.
Arch Ophthalmol (2001) · Rct · n=3640
Antioxidants plus zinc vs placebo for advanced AMD: OR 0.72 (99% CI 0.52-0.98). Zinc alone OR 0.75 (0.55-1.03); antioxidants alone OR 0.80 (0.59-1.09) — neither significant on its own
Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28.
JAMA Ophthalmol (2022) · Cohort · n=3882
10-year lung cancer odds ratio: 1.82 (95% CI 1.06-3.12, P=.02) for beta-carotene assignment vs 1.15 (0.79-1.66, P=.46) for lutein/zeaxanthin
Comparative Effectiveness of Nutritional Supplements in the Treatment of Knee Osteoarthritis: A Network Meta-Analysis
Nutrients (2025) · Meta analysis · n=4599
Bayesian rankings indicated Boswellia had the highest probability of being most effective for pain and stiffness, with krill oil and curcumin showing potential for function improvement.
Oral herbal medicines marketed in Brazil for the treatment of osteoarthritis: A systematic review and meta-analysis
Phytotherapy research : PTR (2017) · Meta analysis · n=1741
Z. officinale showed improvement of pain over placebo.
Oral herbal therapies for treating osteoarthritis
The Cochrane database of systematic reviews (2014) · Meta analysis · n=5980
Seventeen studies of confirmatory design (sample and effect sizes pre-specified) were mostly at moderate risk of bias.
The Cochrane review of oral herbal therapies (PMID 24848732) found high-quality evidence from two trials (85 people) that 100 mg a day of an enriched Boswellia serrata extract for 90 days cut pain by 17 points on a 0 to 100 scale against placebo, with fewer adverse events than placebo in one trial. Effectiveness is that pain reduction. A 250 mg dose of enriched extract showed possible benefit in low-quality evidence from a single small study, so it is plotted flat, not higher. Trials of 100 mg Aflapin a day for 30 and 180 days also reduced knee pain against placebo (PMID 35512759, 39700461). A 999 mg dose of a non-enriched extract is a different product and is not plotted. The Cochrane authors state that the optimal daily dose is still to be determined.
AI-estimated from published studies. Interpret as directional guidance.
Boswellia has a higher evidence score (7.5/10 vs 7/10) and wins in 3 of 3 categories.
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.